64Cu-FBP8 for Imaging Blood Clots

Positron Emission Tomography (PET) Imaging of Thrombosis

Recruiting Phase 1 Interventional Study
Atrial Fibrillation COVID-19 Cancer Thrombosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
165 (estimated)
Sponsor
Massachusetts General Hospital · Other
Who this trial is looking for

This trial is looking for patients with conditions like cancer, COVID-19, or atrial fibrillation to help test a new imaging method for detecting blood clots in the body. Participants will undergo a special imaging procedure using a tracer called 64Cu-FBP8.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with cancer
  • I have a positive test for COVID-19 within the last month
  • I have a history of atrial fibrillation
  • I have been evaluated for blood clots using a recent TEE or have one scheduled

You may not be able to join if

  • I am under 18 years old
  • I have a cardiac pacemaker or other electrical implants
  • I am pregnant or breastfeeding
  • I am claustrophobic and cannot tolerate the imaging procedure
  • I weigh over 300 lbs for the MRI table
  • I am unable to lie comfortably during the imaging procedure
  • I have had a stroke or heart attack in the last 3 months
  • I am not able to give written consent

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
For Atrial Fibrillation Patient subjects: * History of atrial fibrillation or paroxysmal atrial fibrillation; * Retrospective enrollment: TEE to evaluate LAA within the last 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE…
Contacts

David E Sosnovik, MD

617-724-3407

sosnovik@nmr.mgh.harvard.edu

CONTACT

Anne L Philip, MPH

617-726-0431

alphilip@mgh.harvard.edu

CONTACT